ライフサイエンスコーパス: chemoresistant

1 ids colonization and renders the tumor cells chemoresistant.

2 ion effects, and patients bearing Mt p53 are chemoresistant.

3 ial to mediate tumor regrowth are relatively chemoresistant.

4 which are frequently radiation-resistant and chemoresistant.

5 n aggressive B cell lymphoma that is largely chemoresistant.

6 an self-renew and are highly tumorigenic and chemoresistant.

7 with either chemosensitive (50 patients) or chemoresistant (44 patients) relapse, including 22 who f

8 ci at 4092 genes becoming hypermethylated in chemoresistant A2780/cp70 compared with the parental-sen

9 erS5/6 activities (approximately twofold) in chemoresistant ABCB1(high) (A498, Caki-1) compared with

10 In this study, we demonstrated that chemoresistant acute myeloid leukemia (AML) cells had a

11 apoptotic death and selective eradication of chemoresistant AML cells in vitro and in vivo.

12 ses the outgrowth of a pre-determined set of chemoresistant AML clones with stemness properties, inst

13 Importantly, more chemoresistant AML LSCs appeared to be retained in Lama4

14 etic stem cells, leukemic blasts, as well as chemoresistant AML were all consistently hallmarked by i

15 potential importance of WIT-1 methylation in chemoresistant AML.

16 Apaf-1-negative melanomas are invariably chemoresistant and are unable to execute a typical apopt

17 ease progression at 1 year for patients with chemoresistant and chemosensitive disease were 75% and 2

18 on and illustrate a therapeutic strategy for chemoresistant and desmoplastic CRCs.

19 -arr1, ARRB1) links Wnt signaling to acquire chemoresistant and EMT phenotype.

20 We induce chemoresistant and G0 leukemic cells by serum starvation

21 cancer cells endowed with high tumorigenic, chemoresistant and metastatic potential.

22 isolated from ovarian cancer cell lines were chemoresistant and preferentially grew tumors, compared

23 r Notch, but these cells are also relatively chemoresistant and provide trophic support to neuroendoc

24 erexpressed in many human cancers, including chemoresistant and radioresistant breast cancer cells, b

25 herapies may be missing the subpopulation of chemoresistant and radioresistant cancer stem cells (CSC

26 ed a chemosensitive SCLC PDX model to become chemoresistant and resulted in sensitivity to inhibition

27 Adult T-cell leukemia (ATL) is a highly chemoresistant and usually fatal T-cell malignancy due t

28 irst 3 years for the chemosensitive relapse, chemoresistant, and induction failure groups were 61%, 4

29 tiple stem cell characteristics, were highly chemoresistant, and were enriched in xenografts residual

30 CK5-positive cells were chemoresistant as determined by fourfold reduced rate of

31 of DNA-PKcs in vivo resensitizes inherently chemoresistant ATM-deficient tumors to genotoxic chemoth

32 e emerged as effective treatment options for chemoresistant B cell acute lymphoblastic leukemia (B-AL

33 ROR1 is overexpressed in chemoresistant BC where it correlates with poor therapy

34 emoresistance is critical in order to combat chemoresistant BC.

35 growth in both the chemosensitive BL0440 and chemoresistant BL0269 models.

36 llagen type III is enriched in patients with chemoresistant bladder cancer after neoadjuvant chemothe

37 timal tri-drug combination in eight distinct chemoresistant bladder cancer cell lines.

38 se findings provide a rationale for treating chemoresistant bone metastasis of PCa with inhibitors of

39 Malignant gliomas are highly invasive and chemoresistant brain tumors with extremely poor prognosi

40 restoration of PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells.

41 with olaparib can restore the sensitivity of chemoresistant BRCA1/2-deficient cells.

42 ful predictive biomarker for a population of chemoresistant breast cancer patients.

43 (TNBC), contributing to the maintenance of a chemoresistant breast cancer stem cell (BCSC) population

44 eatures, and may arise from an earlier, more chemoresistant breast epithelial precursor than basal-li

45 splantation (NMAT) infrequently cures active chemoresistant, bulky, or aggressive B-cell lymphoma (B-

46 Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could b

47 PSP94 peptide derivative PCK3145 suppresses chemoresistant cancer cell and tumor growth in vitro and

48 TT and cellular HDAC assays on sensitive and chemoresistant cancer cell lines as well as HDAC profili

49 acious therapeutics against solid tumors and chemoresistant cancer cell lines.

50 e protein, ABCG2, is up-regulated in certain chemoresistant cancer cells and in the mammary gland dur

51 iant cancer cells (PGCCs) are multinucleated chemoresistant cancer cells found in heterogeneous solid

52 eased expression of miR-9-3p and miR-9-5p in chemoresistant cancer cells may support their validation

53 dentification of medicinal compounds against chemoresistant cancer cells via new mechanism of action

54 the critical role of PGCCs as aggressive and chemoresistant cancer cells, as well as their ability to

55 in rapid loss of this prosurvival protein in chemoresistant cancer cells.

56 signaling, amplifying the TRIM37 network in chemoresistant cancer cells.

57 incurable due to the inability to eradicate chemoresistant cancer stem-like cells (sCSC) that are li

58 lanoma is a highly aggressive and frequently chemoresistant cancer, the incidence of which continues

59 rationally designed therapy for metastatic, chemoresistant cancers and might overcome the problems a

60 In contrast, chemoresistant cancers and normal tissues were poorly pr

61 p53 mutations often occur in aggressive and chemoresistant cancers but are rarely observed in melano

62 e other hand, kinase inhibitor-resistant and chemoresistant cancers have increased cilia and increase

63 have potential therapeutic implications for chemoresistant cancers, especially of brain tumours wher

64 n D1 is observed in many aggressive forms of chemoresistant cancers, these findings provide insight i

65 lanoma represent biologically aggressive and chemoresistant cancers.

66 ts of targeting RAD6 with SMI#9 for managing chemoresistant cancers.

67 grafts to generate paired chemosensitive and chemoresistant cancers.

68 ce that this agent can preferentially target chemoresistant CD133(+) cells with CSC character in SCLC

69 es and c-MYC protein were upregulated in the chemoresistant CDX model, while MYC/MAX dimerization blo

70 al inhibition of NO synthase re-sensitizes a chemoresistant CDX progression model in vivo, revealing

71 tumours at relapse following chemotherapy or chemoresistant cell lines derived at the time of patient

72 NA rescue functional assays on 12 strains of chemoresistant cell lines each against cisplatin, 5-fluo

73 tients, and alternative approaches to target chemoresistant cells are needed.

74 Our results show that drugs resensitizing chemoresistant cells are superior to those aimed at trig

75 ling cells with those that target quiescent, chemoresistant cells associated with nutrient and oxygen

76 ature myeloid blast cells with stem-like and chemoresistant cells being retained in the bone marrow t

77 oma bulk populations and indicate that these chemoresistant cells can be specifically targeted via AB

78 restingly, direct delivery of ATP into cross-chemoresistant cells destabilized HIF-1alpha and inhibit

79 d not survive glucose deprivation, while the chemoresistant cells displayed adaptability.

80 These chemoresistant cells exhibited a corresponding upregulat

81 d it represents hematopoietic stem cells and chemoresistant cells from several solid tumors.

82 Recent studies have reported that chemoresistant cells have an increased oxidative state i

83 tic approach to mitigate the impact of these chemoresistant cells in cancer progression and to improv

84 genotoxic drug treatment favors selection of chemoresistant cells in genetically heterogeneous tumors

85 de evidence that SP is an enriched source of chemoresistant cells in human melanomas, and suggest tha

86 3K activation can lead to the development of chemoresistant cells in prostatic carcinomas through the

87 <30% due to the persisting dissemination of chemoresistant cells in the peritoneal fluid and the imm

88 oxygen species (ROS)-mediated death of even chemoresistant cells independently of p53 status.

89 Chemoresistant cells must consume excess resources to ma

90 MCAM depletion in chemoresistant cells reduced cell proliferation and redu

91 GPT2 knockout in chemoresistant cells restored the metabolic phenotype to

92 ed that MCAM modulated lactate production in chemoresistant cells that exhibit a distinct metabolic p

93 In tumours, accumulation of chemoresistant cells that express high levels of anti-ap

94 tion, which serves to maintain slow cycling, chemoresistant cells through an IL1beta/IL8/CXCR1 cytoki

95 Inhibition of Akt is required to sensitize chemoresistant cells to CDDP in a p53-dependent manner,

96 e C-terminal GSN fragment (C-GSN) sensitized chemoresistant cells to CDDP, intact GSN and its N-termi

97 y undergoing clinical evaluation, sensitized chemoresistant cells to cisplatin.

98 t which is known to favor the development of chemoresistant cells.

99 g also facilitated CDDP-induced apoptosis in chemoresistant cells.

100 y proliferate at the expense of the less fit chemoresistant cells.

101 ynergize with chemotherapeutic agents across chemoresistant cellular and mouse models.

102 erapy options, particularly in patients with chemoresistant clones carrying STAT5BN642H.

103 Certain chemoresistant colon cancer cells are therefore exquisit

104 c transaminase 2 (GPT2), were upregulated in chemoresistant compared to chemosensitive cells.

105 displayed a glycolytic phenotype while their chemoresistant counterparts (C200 and PEO4) exhibited a

106 vestigated CSC properties in newly developed chemoresistant CRC cell lines and sought to identify tar

107 Chemoresistant CRC cells are enriched for CSC markers an

108 ore effective therapy should target both the chemoresistant CSCs and the proliferating epithelial cel

109 nt, indicating that paclitaxel enrichment of chemoresistant CSCs is less dependent on microenvironmen

110 limited toxicity in mice with aggressive and chemoresistant diffuse intrinsic pontine glioma.

111 scription modulator that is overexpressed in chemoresistant, diffuse large B-cell lymphomas (DLBCLs).

112 eous blocks in both pathways correlated with chemoresistant disease (92% of patients with chemoresist

113 Adverse OS was associated with chemoresistant disease (relative risk [RR], 2.9), more t

114 Resurgence of chemoresistant disease after primary therapy typifies ep

115 ith high-grade NHL, mantle cell lymphoma, or chemoresistant disease had a poor outcome.

116 However, chemoresistant disease is still problematic.

117 ugh their contribution in development of the chemoresistant disease remains elusive.

118 Developing effective strategies to eradicate chemoresistant disease requires experimental models that

119 OS were 42% and 55%, whereas for those with chemoresistant disease the PFS and OS were 22% and 29%.

120 chemoresistant disease (92% of patients with chemoresistant disease versus 33% of patients with chemo

121 nitial therapy but is prone to relapses with chemoresistant disease, indicating the need for novel th

122 typically followed by recurrence with lethal chemoresistant disease.

123 velop recurrence, which rapidly evolves into chemoresistant disease.

124 nal non-operable patients with recurrent and chemoresistant disease.

125 and that such expression may be a marker of chemoresistant disease.

126 al chemosensitivity followed by emergence of chemoresistant disease.

127 here are no standardized treatments for this chemoresistant disease.

128 disease and the near guaranteed emergence of chemoresistant disease.

129 vanced-stage patients relapse and succumb to chemoresistant disease.

130 l metastasis and about 50% will relapse with chemoresistant disease.

131 lethal gynecological cancer, often leads to chemoresistant diseases.

132 We show that chemoresistant DTCs occupy the perivascular niche (PVN)

133 ted strong synergistic antitumor activity in chemoresistant EC cell lines, HEC-1B and ARK-2 cells.

134 to a marked reduction in tumor growth in two chemoresistant EC mouse xenograft models.

135 VEGF receptors, reduced proliferation of the chemoresistant EOC cells through induction of G2/M cell

136 Investigations in clinical specimens of chemoresistant EOC tissues confirmed increased recruitme

137 bitors have demonstrated limited activity in chemoresistant EOC.

138 potential of dacomitinib in treatment of the chemoresistant EOC.

139 nd an increase in endothelial cells whilst a chemoresistant epithelial stem cell population correlate

140 diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL.

141 ly chemosensitive, but rapidly relapses in a chemoresistant form with an overall survival of <5%.

142 C/EBPbeta is associated with metastatic and chemoresistant forms of breast cancer.

143 rgeted therapeutic agents for metastatic and chemoresistant gestational trophoblastic neoplasia.

144 ited the proliferation of chemosensitive and chemoresistant glioma cells but did not display toxicity

145 therapy for a poor prognosis and frequently chemoresistant group of patients with MM, for whom thera

146 e, we report higher gelsolin (GSN) levels in chemoresistant gynecological cancer cells compared with

147 d be investigated further as a treatment for chemoresistant HB.

148 Chemoresistant hepatoblastoma (HB) is associated with po

149 In chemoresistant hepatospheres, CD47 was found to be up-re

150 r values, we infer that most patients harbor chemoresistant HGSC cells at diagnosis and that, if the

151 utic strategy that could improve outcomes in chemoresistant HGSOC.

152 ol with mechanistic rationale against highly chemoresistant human PaC cells.

153 fibroblast (CAF) polarization (p=0.006) and chemoresistant IL-6/STAT-3 signaling in vivo.

154 In part, a lack of natively metastatic, chemoresistant in vivo models has limited our insight in

155 Because NSCLC is highly chemoresistant, it is, usually not treatable.

156 ilostamide, causes profound growth arrest of chemoresistant KM12C colon cancer cells.

157 in a subset of NB cell lines, including the chemoresistant LA-N-6 cell line.

158 ide but in almost every case becomes rapidly chemoresistant, leading to death within 1 year.

159 Most patients with AML succumb to chemoresistant leukemia stem cells (LSCs), which persist

160 pitulate gene expression profiles of in vivo chemoresistant leukemic and G0 models.

161 a promising strategy to target and eliminate chemoresistant leukemic cells.

162 herapy is a promising strategy for targeting chemoresistant leukemic cells.

163 gulin1-beta1 (HRG1/NRG1), which is higher in chemoresistant lines compared to cisplatin-sensitive cel

164 reduced Akt-activated beta-catenin levels in chemoresistant LSCs and reduced LSC tumorigenic activity

165 agents) could favor elimination of residual chemoresistant lymphoma cells.

166 as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility o

167 denocarcinoma (PDAC) is a highly metastatic, chemoresistant malignancy and is characterized by a dens

168 eritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options

169 n hormone therapy resistant (MDA-MB-231) and chemoresistant (MCF-7TN-R) breast cancer cells.

170 s P-gp expression and is associated with the chemoresistant mechanisms of metastatic human breast can

171 cancer cell lines (MDA-MB-231) to study the chemoresistant mechanisms regulated by miRNAs.

172 hich points to the existence of a relatively chemoresistant melanoblast-like cell population residing

173 ed for cytotoxic activity against a panel of chemoresistant melanoma cell lines, and it was found tha

174 nd inducer of cell death in otherwise highly chemoresistant melanoma cells.

175 stigating nanoparticle treatment options for chemoresistant melanomas.

176 rapy often fail because of the recurrence of chemoresistant metastases.

177 or, primary (testicular and mediastinal) and chemoresistant metastatic human GCTs, we show that the p

178 res enriched in CR-CSCs, including four from chemoresistant metastatic lesions, were used for in vitr

179 Persistence of chemoresistant minimal residual disease (MRD) plasma cel

180 Finally, BI extended mouse survival in a chemoresistant model and significantly improved chemothe

181 Multiple chemoresistant models demonstrated suppression of SLFN11

182 rapeutic efficacy in both chemosensitive and chemoresistant models of small cell lung cancer.

183 in several types of cancer cells, including chemoresistant multiple myeloma (MM) cells.

184 tic approach to target highly aggressive and chemoresistant MYC-activated cancers.

185 rmacological inhibition of USP7 resensitized chemoresistant MYCN-overexpressing PDX models to chemoth

186 ts, but these are short-lived because of the chemoresistant nature of hormone-refractory prostate can

187 e-independent, and likely contributes to the chemoresistant nature of RCCs.

188 Blocking Y5R in chemoresistant NB cells rich in this receptor sensitized

189 gue AN-238 provides an effective therapy for chemoresistant neoplasms such as RCC.

190 Drug efflux pump ABCB1 is overexpressed in chemoresistant neoplasms where it effluxes various chemo

191 d 1 mg/kg/day for 28 days) were evaluated in chemoresistant neuroblastoma-bearing mice and compared w

192 of cancer stem cells markers and sensitized chemoresistant OC cells to carboplatin.

193 e CD55 S/T domain is sufficient to sensitize chemoresistant OC cells to cisplatin.

194 rom chemoresistant patients, and enriched in chemoresistant OC cells.

195 ide leverage to treat ovarian cancer that is chemoresistant on the basis of ineffective apoptosis.

196 ival rates remain at ~70%, but patients with chemoresistant or metastatic disease have extremely poor

197 herefore, it would be beneficial to identify chemoresistant or refractory patients early during thera

198 DM2-overexpressing cancer cells are commonly chemoresistant, our findings suggest that this naturally

199 of SYK and EGFR as a promising treatment for chemoresistant ovarian cancer by disrupting DNA synthesi

200 Dual inhibition of SYK and EGFR in chemoresistant ovarian cancer cells elicited a synergist

201 Chemoresistant ovarian cancer cells showed increased oxi

202 high abundance from both chemosensitive and chemoresistant ovarian cancer cells via exosomes.

203 C down-regulation in both chemosensitive and chemoresistant ovarian cancer cells.

204 e the therapeutic utility of MePS2 siRNAs in chemoresistant ovarian cancer mouse models via targeting

205 ion exerts synergistic anticancer effects in chemoresistant ovarian cancer, providing a strategy to t

206 to prevent the development of recurrent and chemoresistant ovarian cancer.

207 s the PD-L1/PD-1 and CD80/CTLA-4 pathways in chemoresistant ovarian cancer.

208 of GLS inhibitor and PARP inhibitor to treat chemoresistant ovarian cancers, especially those with hi

209 for the development of effective therapy for chemoresistant ovarian cancers.

210 of neoplasms, but particularly in recurrent chemoresistant ovarian carcinomas, suggesting a biologic

211 Lupeol significantly sensitized chemoresistant PaC cells to undergo apoptosis by recombi

212 Glutaminase inhibitors sensitized chemoresistant pancreatic cancer cells to gemcitabine, t

213 ucine) as an adjuvant treatment to sensitize chemoresistant pancreatic cancer cells.

214 by the selective enrichment of intrinsically chemoresistant pancreatic cancer stem cells that are equ

215 or chemical inhibition of Wnt signaling in a chemoresistant patient-derived xenograft (PDX) model of

216 These miRNAs effectively suppressed chemoresistant patient-derived xenograft growth in vivo,

217 us of a subset of OC specimens, ascites from chemoresistant patients, and enriched in chemoresistant

218 help to avoid application of chemotherapy to chemoresistant patients.

219 tients in chemosensitive relapse, and 7% for chemoresistant patients.

220 ognostically relevant in MM and may identify chemoresistant PCs in vitro.

221 d be already present at the MRD stage, where chemoresistant PCs show a singular phenotypic signature

222 tor in chemoresistant SCLC cell lines and in chemoresistant PDX compared with matched treatment-naive

223 with ORY-1001-induced NOTCH activation in a chemoresistant PDX model.

224 A1-mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sen

225 ment of human ovarian cancer (OVCA), and the chemoresistant phenotype in OVCA cells is associated wit

226 membrane scaffold, CD82, contributes to the chemoresistant phenotype of AML.

227 tyrosine kinase activity is required for the chemoresistant phenotype of HER-2/neu-overexpressing NSC

228 NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype.

229 ly modified histones, which correlate with a chemoresistant phenotype.

230 pithelial-mesenchymal transition (EMT) and a chemoresistant phenotype.

231 the inability of Tie2 activation to induce a chemoresistant phenotype.

232 er cell line PA1 leads to an increase in the chemoresistant phenotype.

233 contribute to the development of a radio- or chemoresistant phenotype.

234 oxicity and thereby may contribute to a more chemoresistant phenotype.

235 c stroma, which contribute to the profoundly chemoresistant phenotype.

236 downstream of Dll1 and is associated with a chemoresistant phenotype.

237 creased metabolic activity associated with a chemoresistant phenotype.

238 e case of invasive cancer phenotypes, a more chemoresistant phenotype.

239 tatic samples were characterized as having a chemoresistant phenotype.

240 The chemoresistant population in recurrent osteosarcoma is s

241 (Lmo2Tg) mouse model in which we can monitor chemoresistant preleukemia stem cells (pre-LSCs) and leu

242 fer both tumor cell heterogeneity as well as chemoresistant properties.

243 the fallopian tubes that has a high rate of chemoresistant recurrence and low five-year survival rat

244 nt survival, effective treatments addressing chemoresistant recurrences are particularly needed.

245 derived from leukemia patients experiencing chemoresistant relapse that were exposed to these nanopa

246 tors (DNMTi, hypomethylating drugs) prevents chemoresistant relapses.

247 Thus, our results establish a chemoresistant role for RIP1 that maintains inhibitor of

248 iously unexplored therapeutic target in this chemoresistant sarcoma.

249 growth and mitochondrial dysfunction in the chemoresistant SCLC cell line H69AR.

250 s a markedly upregulated surface receptor in chemoresistant SCLC cell lines and in chemoresistant PDX

251 nt mutations was found to be associated with chemoresistant secondary lymphomas.

252 enocarcinoma, and is further enhanced during chemoresistant selection.

253 inhibited the growth of three of five lethal chemoresistant serous adenocarcinoma PDXa models without

254 strategy poised for testing in patients with chemoresistant serous ovarian cancer.

255 that TPCs can reversibly enter a quiescent, chemoresistant state and thereby underscore the need for

256 ke Fusobacterium species induce a quiescent, chemoresistant state in cancer cells in the colon by dis

257 itical role in acquiring and maintaining the chemoresistant state in ovarian cancer.

258 pies; however, essentially all progress to a chemoresistant state.

259 el molecular marker for a distinct subset of chemoresistant, stem cell phenotype-expressing tumor cel

260 Intriguingly, three metastatic and chemoresistant subclones, S2-CP9, S2-LM7AA, and S2-013,

261 , suppress proliferation of the less fit but chemoresistant subpopulations.

262 tial cause of cancer relapse is pretreatment chemoresistant subpopulations.

263 Metaplastic breast cancer (MpBC) is a highly chemoresistant subtype of breast cancer with no standard

264 f pluripotency markers (NANOG and POU5F1) in chemoresistant teratomas or transformed carcinomas.

265 DKK4 and NOTCH signaling levels and are more chemoresistant than paired subcutaneous xenografts.

266 ng actionable targets in treatment-naive and chemoresistant TNBC is a critical unmet medical need.

267 key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing th

268 Leukemias with NT5C2 mutations are chemoresistant to 6-mercaptopurine yet show impaired pro

269 The chemoresistant traits of BORG depend upon its robust act

270 ay in TECs and converts naive tumor cells to chemoresistant TSCs, thereby facilitating their invasive

271 rug that, by inhibiting Tim16, may sensitize chemoresistant tumor cell to proapoptotic stimuli.

272 is largely attributed to the development of chemoresistant tumor cells.

273 re generally attributed to subpopulations of chemoresistant tumor cells.

274 cell renal cell cancer (CC-RCC) is a highly chemoresistant tumor characterized by frequent inactivat

275 sophageal adenocarcinoma is a heterogeneous, chemoresistant tumor for which the availability and size

276 s a molecular marker for distinct subsets of chemoresistant tumor-initiating cell populations in dive

277 ial for STI571 in patients afflicted by this chemoresistant tumor.

278 orubicin and cisplatin chemotherapy, and all chemoresistant tumors adopted a p53-like phenotype after

279 JAK2 inhibitor CYT387 reduced progression of chemoresistant tumors and increased survival.

280 plastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticit

281 patients bear inoperable, locally advanced, chemoresistant tumors demonstrating the urgent need for

282 evance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear.

283 d the superiority of metronomic protocols in chemoresistant tumors in vivoCancer Res; 77(17); 4723-33

284 tection-challenged BRCA1-deficient naive- or chemoresistant tumors require SMARCAD1-mediated active f

285 lpha, the inhibitor of NF-kappaB, sensitizes chemoresistant tumors to the apoptotic potential of TNFa

286 Patients with chemoresistant tumors were twice as likely to have high

287 making it an attractive anticancer agent for chemoresistant tumors with enhanced antiapoptotic activi

288 ere established from both chemosensitive and chemoresistant tumors, and nearly 30% of the PDX models

289 etastatic JAK-STAT3 pathway was activated in chemoresistant tumors, and treatment with the JAK1/JAK2

290 in tumors are among the most common and most chemoresistant tumors.

291 ognosis and present with more aggressive and chemoresistant tumors.

292 say using live mitochondria from RASAL2-high/chemoresistant tumour cells demonstrated attenuated rele

293 ncy of p53 mutations observed in this highly chemoresistant tumour type.

294 cer cells, including hormone-independent and chemoresistant types.

295 ncer stem cells (CSC) are hypothesized to be chemoresistant, we investigated CSC properties in newly

296 chter transformation (DLBCL-RT) is typically chemoresistant with poor prognosis.

297 onic lymphocytic leukemia (CLL) is typically chemoresistant, with a poor prognosis.

298 In vivo chemoresistant xenograft models, an unbiased genome-wide

299 in 3D-cultured cell lines, tumor organoids, chemoresistant xenografts, syngeneic tumors and PDX mode

300 in the more chemosensitive WERI, but not the chemoresistant Y79 line.